Estrella Immunopharma (ESLA) Stock Soars 18%: What’s Driving the Surge
Estrella Immunopharma shares climbed 17.91% after hours following an update on its EB103 cancer therapy trial and early safety results.
Share
Why It Matters
Estrella shared good early news about a cancer medicine they are testing. When you see a stock jump big like this, watch if the medicine keeps working well in more tests.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.